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Abstract
The human papillomavirus (HPV) was the first virus known to induce carcinogenesis and is associated with cancers of the uterine cervix, 
anogenital tumors and malignancies of the head and neck. This paper reviews the structure and basic genomic characteristics of the 
virus and outlines the clinical involvement of the main HPV serotypes, focusing on the carcinogenic role of HPV-16 and 18. The mecha-
nisms that occur in the development of cervical neoplasia due to the oncogenic proteins E6 and E7 which interfere with the regulation of 
the cell cycle through their interaction with p53 and retinoblastoma protein are described. Epidemiological factors, diagnostic tools and 
the management of the disease are also reviewed, along with the available vaccines to prevent the viral infection. Insights on current 
research on involvement of oxidative stress and micro-RNAs in cervical carcinogenesis are also explored as they may unlock new means 
of diagnosis and treatment in the future. 
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Introduction
The human papillomaviruses (HPVs) are a group of small viru-
ses containing deoxyribonucleic acid (DNA) which belong to the 
Papillomaviridae family. They are highly ubiquitous and proper-
ly adapted to their hosts, with the ability to effectively mask 
themselves from immune responses. Over 200 types of viruses 
have been identified and classified into 16 genera, and most of 
these affect humans. These viruses primarily target differentia-
ting squamous epithelium and are associated with cutaneous 
infections, in which almost any part of the human skin can be 
affected, and mucosal infections. HPV infection is a risk factor 
for malignancy of the uterine cervix by playing an integral role 
in carcinogenesis through the action of its genomic products.1
HPV Structure
HPVs are spherical, non-enveloped particles with an approxima-
te diameter of 52–55 nm and a molecular weight of about 5×106 
Da. Their capsid has an icosahedral symmetry and is compo-
sed of 72 capsomeres, each possessing five identical subunits 
and hence a five-fold symmetry.2 Of these capsomeres, 60 are 
hexavalent (exhibit six-coordination), whilst the remaining 12 
are pentavalent.3
The HPV Genome
The nucleic acid core of the virion consists of supercoiled dou-
ble-stranded closed circular DNA of approximately 8,000 base 
pairs. The open reading frame (ORF) size is larger than 400 
bases and found on one strand exhibited in the form of arcs 
external to the circular genome. All viral messenger ribonu-
cleic acid (mRNA) transcripts are derived from one strand.4 
Both the capsid and genome morphology are similar across 
the Papillomaviridae family, but differences in the genomic or-
ganization as well as size and sequences of nucleotides and 
amino acids have allowed the separation of papillomaviruses 
into separate groups.5
The genome of all papillomaviruses consists of three unequal 
regions. The upstream regulatory region (URR) is also known 
as the long control region (LCR) or the non-coding region (NCR) 
and constitutes around 10% of the entire genome.3 The early 
region occupies approximately half the genome and is further 
divided into two large and many smaller reading frames: E1–E2 
and E4–E7, respectively.3 E6 and E7 are directly involved in 
the development of cervical cancer.2 The late region completes 
the remaining 40% of the genome and contains two genes: L1 
and L2.3 
HPV Classification and Serotypes
Although HPV is commonly implicated in cases of cervical can-
cer, this is not the sole clinical scenario in which the virus is 
involved. There is a great diversity of HPV types that cause 
various lesions, which may overlap across the different types. 
HPV serotypes are genetically diverse from each other and, in 
fact, the standard systematic classification system states that 
a specific HPV type must possess a complete genome in which 
the L1 nucleotide sequence differs from that in any other HPV 
genome by a minimum of 10%. HPV types are denoted numeri-
cally, in the chronological order of when they were discovered.2 
There are over 200 types of HPV and these are further classified 
into 16 genera.1 There are further subdivisions known as HPV 
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species, which represent serotypes that are genetically distinct 
but are characterized by similar biological activity. In addition, 
there are also other HPV subtypes and variants that are 2–10% 
and <2% dissimilar.2 
Due to the fact that there is a multitude of HPV serotypes and 
that they have evolved to occupy various biological niches,2 
they are often divided into three groups: cutaneous, mucocuta-
neous, and the viruses associated with epidermodysplasia ve-
rruciformis.1 The Beta genus encompasses the cutaneous HPVs, 
together with some members of the Gamma and Mu genera. 
The Alpha genus is mainly characterized by the mucosal sero-
types but also some cutaneous types that cause warts.5 HPVs 
can also be grouped depending on the regions of the body that 
they infect and the diseases they cause.2 
There is yet another classification system for HPVs based on 
their oncogenic potential. In this system, the viruses are di-
vided into three groups depending on whether they cause an 
infection which has a low, intermediate or high risk of resulting 
in a malignancy,5 as can be seen in Table 1. 
Epidemiology
The anogenital type of infection is the most common sexually 
transmitted infection (STI) in the United States—it is estima-
ted that 6.2 million people acquire the infection every year. 
The infection tends to be more common in adolescents and 
young adults. Clinical studies have shown that the prevalence 
in adolescent girls is normally around 30% and can even go 
up to 64%. Another study explained that four years after first 
sexual intercourse, over half of the young woman population 
were affected by cervical HPV infection. The same study also 
reported that HPV can be transmitted via nonpenetrative se-
xual behavior, but the probability is lower than acquiring the 
infection through penetrative sex. Apart from sexual behavior 
and history, studies in the United States reported that an age 
of less than 25 years is also a risk factor for the infection and 
the prevalence tends to decrease after this age, except for one 
cohort study in Costa Rica, which found that the prevalence 
rises again after 40. Furthermore, men and women seem to 
have similar rates of HPV infection.6 Figure 1 illustrates the 
prevalence of HPV infection according to age. 
The detection of high-risk HPV in virgins, neonates and children 
provides evidence that the sexual route is not the sole means 
of HPV transmission. Both low- and high-risk HPV serotypes can 
be transmitted via non-sexual routes such as physical contact, 
shared bathing and infected fomites. It appears that the trans-
mission of high-risk HPV from mother to infant occurs during 
parturition as the neonate descends through the infected birth 
canal. This is more likely to occur in women having markedly 
higher amounts of HPV DNA, such as HPV-16, than in those 
having less DNA. Furthermore, a case of two mothers with both 
HPV-16 and 18 infections gave birth to neonates with similar 
co-infection.7
The state of pregnancy seems to increase the likelihood of 
developing genital HPV infections. This was demonstrated by 
a study which showed that 52.5% of patients tested positive 
for HPV DNA during the third trimester of pregnancy, compa-
red to 17.5% after parturition. Physiological explanations for 
this finding may be that the hormone profile during pregnancy 
increases the transcription of HPV genes due to interactions 
between glucocorticoids and their response elements present 
in the non-coding region of HPV-16. Additionally, pregnancy is a 
state of immunosuppression. HPV infections can also be trans-
mitted during pregnancy itself across the placenta and through 
amniotic fluid. In fact, a study revealed the presence of HPV 
DNA in 75% of amniotic fluids taken from women who were 
positive for cervical HPV DNA.7
Interestingly, the first evidence that suggested an association 
between HPV and cancer emerged from research in the 1970s 
on skin cancer in patients suffering from epidermodysplasia 
verruciformis,4 which is a rare autosomal recessive disorder 
associated with the mutation of one of the two genes: EVER1 
and EVER2 located on chromosome 17.1 This disorder is charac-
terized by flat warts or pityriasis-like lesions that are caused 
by infections with HPV types 5, 8 or 17. These warts resulted in 
skin cancers in 20% of patients, mostly in areas exposed to the 
sun.4 It appears that the mutated genes code for transmembra-
ne proteins that function in zinc homeostasis, and their loss 
results in the transcription of the E6 and E7 genes,1 thereby 
facilitating carcinogenesis.
Cervical cancer is the second most common malignancy in wo-
men around the world and affects an average of 35 per 100,000 
women.1 The interest in the association between HPV and can-
cer was greatly magnified when HPV types 16 and 18 were 
discovered in cervical cancers and preneoplastic dysplasia, 
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Table 1. HPV Serotypes Grouped according to Oncogenic Risk
Risk Category HPV Serotype Relation to Cervical Cancer
Low 6, 11 Rarely associated with cervical cancer and mostly causes 
genital warts
Intermediate 22, 35, 39, 52, 56, 
58, 59, 68
Present in around 25% cases and are rarer than the high-risk 
serotypes
High 16, 18, 31, 45 Present in around 75% of cases, the commonest types being 
16 and 18
Adapted from Blundell R, Camilleri G. The human papillomaviruses (HPVs) and HPV DNA testing. In: Blun-
dell R, ed. Infertility. Saarbrücken (Germany): Lambert Academic Publishing; 2013. p. 57-82. Reprinted with 
permission from Blundell R.
Figure 1. Prevalence of High-Risk HPV Infection among Females Undergoing Cervical 
Screening
Compiled using information from Kitchener H, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A et 
al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer. 
2006;95(1):56-61.
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lesions that can predispose one to malignancy of the uterine 
cervix.4 It has been found that HPV DNA features in over 99% 
of cervical cancer cases; however, the most common high-risk 
serotype varies across countries, ethnicities and socioeconomic 
statuses. In a study of more than 30,000 cervical cancers, the 
International Agency for Research on Cancer (IARC) demonstra-
ted that amongst the most common HPV serotypes responsible 
for causing cervical malignancy (16, 18, 58, 33, 45, 31, 52, 35, 
59, 39, 51, 56), HPV 16 causes over 50% whilst HPV 16 and 18 
cause more than 70% of cases worldwide. HPV serotypes 18 
and 45 are implicated in the more aggressive cervical adeno-
carcinomas.1
It has been found that sustained infection with high-risk HPV 
serotypes is the most fundamental risk factor in the develo-
pment of precursor lesions for cervical cancer. Persistence is 
normally defined as the detection of the same high-risk HPV 
types at >2 visits 4–6 months apart.6 In fact, studies have shown 
that such persistent infections can increase the likelihood of 
developing high-grade precursors of cervical malignancy by 
more than 10 times.6
Pathophysiology
The Cervical Canal and Associated Malignancies
The cervix represents the anatomical transition between the vagi-
na and the uterus. It consists of a canal with two openings: the 
superior internal os which leads into the uterus and the inferior 
external os that opens into the vaginal cavity. The histology of 
the cervical canal is characterized by simple columnar secretory 
epithelium, as opposed to the vaginal cavity, which is lined by 
stratified non-keratinizing squamous epithelium. The epithelia li-
ning the endocervix and exocervix meet at a point known as the 
transition zone, or squamocolumnar junction which corresponds 
to the region of the cervix at the external os.8
The squamocolumnar junction is a highly important cytological 
landmark because it is the site with greatest susceptibility to in-
fection by HPV and where over 90% of malignancies from the lower 
genital tract arise. HPV is known to cause cervical dysplasia and 
cervical intraepithelial neoplasia (CIN), which are likely to progress 
to cervical cancer as a result of sustained infection by high-risk 
HPV.9
As the transition zone involves two epithelial cell types—the glan-
dular and squamous cells—two types of cancers can arise in the 
cervix. The uncontrolled proliferation of the glandular cells of the 
endocervix produces an adenocarcinoma (10–20% of cases, but 
incidence seems to be on the rise in recent years), whereas a 
malignancy of the squamous cells results in squamous cell car-
cinoma. The latter is far more common (80–90% of cases) and is 
often asymptomatic at its initial stages, but can present with coital 
and pelvic pain as well as aberrant vaginal bleeding and discharge 
at later stages.
Life Cycle of the HPV
The process of cervical carcinogenesis is intimately linked to 
the events occurring in the life cycle of the virus, as shown in 
Figure 2. In a stratified squamous epithelium, the cells forming 
the basal layer behave as stem cells and therefore have the 
function to undergo cell division in view of replenishing the 
cells shed from the surface layer. When the basal cell divides 
by mitosis, two daughter cells are produced: one ascends and 
transforms into a terminally differentiated cell, whilst the re-
maining cell resides in the basal layer to maintain the pool of 
dividing cells. The first targets of the virus are in fact the basal 
cells that are accessed through microwounds. HPV virions enter 
the cells by interacting with specific receptors like the alpha-6 
integrin that binds HPV-16. Viral DNA replication commences 
in the basal layers, producing 50–100 copies of the genome 
in each cell. This is accompanied by the expression of the E1 
and E2 proteins, which are necessary for the replication pro-
cess and for the segregation of newly synthesized DNA, thus 
ensuring that infected stem cells remain in the lesion for a 
prolonged timeframe. The virus mainly utilizes host machinery 
to carry out DNA replication, except for the E1 helicase. The 
products of early genes such as E5–E7 are thought to create 
an optimal environment for replication to occur, for example, 
by stimulating DNA replication in the host cell and preventing 
apoptosis.9
As the infected basal cells migrate upwards and differentiate, 
the viral late genes L1 and L2 are transcribed, thereby inducing 
the vegetative stage of the life cycle characterized by drastic 
amplification of the genome.9 It appears that the control of the 
expression of the late genes depends on the state of differen-
tiation of the host cell.4 Once the cell reaches the outermost 
layer of the epithelium, the newly synthesized viral DNA is 
encapsidated to form new virions, which are released, and the 
life cycle is then repeated. As HPVs do not induce complete 
lysis in host cells, new virions are deposited in squames that 
are continuously shed.10 It is interesting to note that the virus 
is well secluded from the host immune system, as the im-
munogenic virions are only assembled in the outer layers of 
the epithelium. Furthermore, the viral proteins E6 and E7 also 
function in keeping the infection asymptomatic by inactivating 
interferon regulatory factor.9
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Figure 2. Life-cycle of the Human Papillomavirus
Compiled using information from Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human pa-
pillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007 Oct;98(10):1505-11.
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Squamous epithelial cells that have been infected by HPV un-
dergo koilocytosis to form cells called koilocytes. These cells 
have an enlarged, darkened and irregularly outlined nucleus 
surrounded by an area of clear space called a perinuclear halo 
and appear vacuolated. This transformation indicates mild ce-
llular dysplasia and represents a highly replicative viral sta-
te. When the extent of dysplasia is moderate or severe, cells 
appear small and multiply even on the outermost layer of the 
epithelium, making the lesion possibly carcinogenic if severe.11
The Role of HPV in Cervical Carcinogenesis
Although HPV is the major risk factor for cervical cancer, many 
researchers speculate that the actual integration of viral DNA in 
the host cell is not a common event and, most of the time, HPV 
infection is resolved relatively quickly by the immune system. 
Even though the viral DNA can cause rapid neoplastic trans-
formation of the infected cells once integrated, the presence 
of HPV DNA in the cell alone is not sufficient to cause cancer 
because other genetic and epigenetic events are probably re-
quired.9 
The two major oncogenic protein products of the HPV virus are 
E6 and E7, which function by altering the regulation of the cell 
cycle and the control of apoptosis. The integration of viral DNA 
disturbs the activity of the E2 protein. This protein is known to 
repress the transcription of E6 and E7 and, therefore, its dis-
ruption leads to dysregulated expression of the oncoproteins. 
Together, these proteins are capable of causing immortalization 
of cells, which maintain their mitotic ability to produce clones 
which also possess the immortalized phenotype and fail to 
undergo terminal differentiation.4
The E7 Oncoprotein
The major characteristic of E7 that enables it to enhance neo-
plastic change is its interaction and subsequent inactivation of 
pRb. The state of phosphorylation of pRb changes according 
to the phase of the cell cycle, being dephosphorylated in G0- 
and G1-phases, phosphorylated throughout the S-phase and 
remains thus until late in the M-phase when it assumes the 
hypophosphorylated form once again via a specific phospha-
tase.4
When dephosphorylated, pRb and associated proteins inhibit 
transcription factors like E2F by binding to them, thereby re-
pressing the expression of genes whose products stimulate 
DNA synthesis and enhancing the progression of the cell cy-
cle. Conversely, when pRb is phosphorylated by G1 CDKs, it 
is unable to bind to E2F and its inhibitory effect is thus lifted, 
allowing the cell to proceed to the S-phase. It is therefore a 
regulator of the G1/S checkpoint. Detection of damaged DNA 
results in the activation of p53, which in turn activates p21, 
a CDK-inhibitor. This binds to and inhibits cyclinE-CDK2 and, 
hence, pRb cannot be phosphorylated, In other words, it can 
inactivate E2F and block the G1/S transition.12 
The E7 protein can bind to the hypophosphorylated form of 
pRb. This interferes with the complex formed between pRb 
and E2F, resulting in the premature progression of the cell into 
S-phase, thereby favoring DNA synthesis and, consequently, 
cell division. E7 is also involved in the enhancement of pRb 
cleavage from its C-terminal by calpain, which is a cysteine 
protease activated by calcium. This is in fact a step that must 
precede the E7-induced proteasomal cleavage of pRb, which in-
volves the 26S proteasome.9 Interestingly, the actual production 
of E7 and its effects on targets like pRb are necessary for the 
replication and completion of the full life cycle of HPV.10 
The E6 Oncoprotein
The E6 protein primarily exerts its neoplastic effect on HPV-in-
fected cells by promoting the ubiquitin-dependent proteosomal 
degradation of p53,9 which is a tumor suppressor gene product 
that protects the cell against the accumulation of harmful mu-
tations that can lead to cancer development. Such mutations 
can be due to DNA damage by physical and chemical muta-
gens, as well as errors during DNA replication. When abnormal 
DNA is detected and p53 is activated, the cell cycle is paused, 
allowing DNA repair to occur before the cell divides. In certain 
circumstances, such as when DNA cannot be effectively repai-
red, apoptosis can be induced for programmed cell death.10 
The concentration of p53 in cells containing E6 such as cervical 
cancer cells is around 2–3 times smaller compared to unin-
fected cells. Its half-life is also markedly reduced. As a con-
sequence, the normal response to DNA damage mediated by 
p53 is not carried out. DNA mutations reside in the genome 
uncorrected and are passed on from one cellular generation to 
another, resulting in their accumulation over time and hence 
causing genomic instability.4 Apart from the lack of checkpoint 
surveillance for DNA damage in cancer cells, they also have an 
intrinsic tendency to favor mutagenesis.10 
The binding of E6 to p53 is not direct and is mediated by E6-as-
sociated protein (E6AP), which is an E3 ubiquitin protein li-
gase. This is part of a class of proteins homologous to the 
E6-AP carboxyl terminus (HECT) E3 ligases that function in the 
recognition of substrates by ubiquinylation machinery targe-
ted for proteosomal degradation. Interestingly, the presence of 
E6 increases the turnover of E6AP, probably as a result of its 
enhanced enzymatic activity in the HPV-infected cellular envi-
ronment.4
Areas of Current Research
Current research is focusing on the role played by oxidative 
stress in HPV-mediated carcinogenesis. Reactive oxygen spe-
cies induce DNA damage and modulate the viral life cycle. 
Studies have proposed a link between the oxidative status of 
infected cells and the persistence or progression of the lesion. 
Oxidative stress also has pro-survival and anti-apoptotic effects 
on infected cells and contributes to the expression of the E6 
and E7 genes. This appears to be a promising area of study, es-
pecially to determine the effects of oxidative stress on chemo-
therapy response and resistance and its potential as a marker 
for diagnostic purposes.13
Micro-RNAs (miRNAs) appear to have a role in cervical carcino-
genesis. They are short strands of non-coding RNA that norma-
lly have short half-life and alter gene expression post-trans-
criptionally. Their deregulation is associated with the onset, 
progression and metastasis of human tumors, including cervi-
cal cancer which exhibits increased and decreased levels of on-
cogenic or tumor suppressive miRNAs, respectively. The E6 and 
E7 proteins are able to modulate miRNAs. It is therefore useful 
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to determine how they can be used as prognostic biomarkers 
by comparing miRNA profiles of normal and transformed cells. 
In addition, future studies can possibly unlock another form of 
cervical cancer treatment involving RNA modification therapy.14
Diagnosis
Cytology and Histology
The introduction of screening programs over the past decades 
has succeeded in reducing the incidences and mortalities of 
cervical cancer.15 The most common and convenient technique 
used to assess the cervix for dysplastic cellular changes is the 
Papanicolau smear. In this procedure, the vaginal orifice is held 
open by a speculum, and a sample of cells is taken from the 
squamocolumnar junction by inserting and rotating a spatula 
through the external os. The smear is fixed onto a slide, stained 
appropriately and observed under the microscope to observe 
the morphology of the epithelial cells. The use of a colposcope 
allows the direct observation of the cervix with a magnified 
epithelium and the possibility of taking a biopsy.1 It has been 
estimated that 40–50% of cervical cancers are diagnosed in wo-
men who take routine cervical cytology screening16 and that four 
out of five women diagnosed with cancer had not taken the test 
in the previous five years.1
Liquid-based cytology has permitted the optimization of the 
quality and consistency of samples by creating uniform cell la-
yers and decreasing the number of poor samples. The presence 
of koilocytes is indicative of productive HPV infection, whilst 
persistent infection manifests itself as highly severe changes 
in the nucleus, mitotic figures and aggregates of pyknotic cells. 
Different classification methods are used for these observations 
(see Table 2), but the Bethesda classification is often the pre-
ferred one and presents two categories: (1) low grade squa-
mous epithelial neoplasia (LSIL), which encompasses samples 
with cells having irregular, larger and well-defined nuclei and 
(2) high grade squamous epithelial neoplasia (HSIL) for samples 
characterized by poorly differentiated and immature, small cells 
having distinct cytoplasmic borders and organized in sheets and 
syncytial groups.1
Histological assessment of samples provides more specific in-
formation about the HPV infection by revealing features such 
as basal hypertrophy, excess surface keratinization and general 
disruption of the epithelium. Cervical intraneoplasia lesions are 
graded according to the fraction of epithelium that exhibits ab-
normalities.1 
Biomarkers
There are various biomarkers that can be used to identify the 
presence and extent of HPV infection and progression of cervical 
malignancy. They can be divided into three groups. The first 
group comprises HPV DNA, RNA and proteins, which prove to be 
highly sensitive and specific for the diagnosis of CIN2 or worse 
lesions in women of 30 years or older and in detecting ade-
nocarcinoma. The second group involves cellular biomarkers, 
which are based on the fact that the E6 and E7 proteins alter 
several pathways that control the cell cycle. For example, as 
the inactivation of pRb leads to an increase in the CDK inhibitor 
p16, the overexpression of this molecule can be detected by 
immunostaining or enzyme-linked immunosorbent assay (ELI-
SA) and hence serves as a marker of cellular transformation. 
The last group includes epigenetic biomarkers which reflect the 
methylation of DNA and hence whether DNA is active or silen-
ced. The state of methylation of the L1 gene appears to be 
associated with the diagnosis of CIN2.17 Table 3 summarizes the 
different types of biomarkers used in the detection of cervical 
cancer lesions. 
Management
The prognosis of cervical cancer and the appropriate treatment 
modality depend on the stage of the cancer, which represents 
the extent of invasion and spread of the tumor. Although cervi-
cal cancer is staged clinically according to International Federa-
tion of Obstetrics and Gynecology guidelines, it is classified in 
three sub-groups for treatment purposes.18 The earliest stages 
(IA
1
 – IIA
1
) represent tumors of the upper one-third of the va-
gina measuring <4 cm, which are treated surgically by coniza-
tion with sufficient excision margins for IA
1
 and conization and 
simple/radical hysterectomy with pelvic lymphadenectomy for 
IIA
2
. Small volume macroscopic disease (IIA
1
- IB
1
) is treated with 
radical hysterectomy, and radical trachelectomy with lymphade-
nectomy is used to preserve fertility.15 Intermediate stages (IB
2 
– IVA) require primary chemoradiation,18 while advanced stages 
(IVB) and patients with persistent incurable disease receive sys-
temic chemotherapy, including cisplatin, carboplatin, paclitaxel, 
topotecan and gemcitabine.19
Current research is focusing on new molecular targets for cer-
vical cancer treatment, such as the use of epidermal growth 
factor receptor (EGFR) antagonists like panitumumab and mul-
titargeted tyrosine kinase inhibitors including imatinib and 
subitinib.18,20 In addition, epigenetic therapy appears to be a 
promising and effective form of treatment for cervical cancer.21 
Investigations on the effects of adding the antiangiogenesis 
agent bevacizumab to chemotherapy used in advanced or recu-
rrent disease are also being carried out.22 
Prevention
The HPV vaccine is an important means of preventing cervical 
cancer, especially if combined with a healthy sexual lifestyle 
and appropriate use of contraceptives. There has been increa-
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Table 2. Classification of Cervical Intraepithelial Lesions
Papanicolau 
Classification
Dysplasia 
Classification
Bethesda Classification Histology Classification
I Negative squa-
mous atypia
NILM (Negative for intraepi-
thelial lesion or malignancy)
Negative
II Squamous 
atypia
ASCUS (Atypical squamous 
cell of unknown significance), 
ASC-H (Atypical squamous 
cells – cannot exclude HSIL)
Squamous atypia
Mild LSIL (Low grade squamous 
intra-epithelial lesions)
CIN1 (Abnormal cells in 1:3 of 
layers; very unlikely to progress)
III Moderate HSIL (High grade squamous 
intra-epithelial lesions)
CIN2 (Abnormal cells including 
mitotic figures in 2:3 of layers 
with loss of stratification and 
differentiation) CIN3 (Abnormal 
cells in all layers; can progress 
to invasive cancer if untreated)
IV Severe CIS 
(Carcinoma in 
situ)
HSIL CIN3 (Abnormal cells in all 
layers; can progress to invasive 
cancer if untreated)
V Carcinoma Carcinoma Carcinoma
Compiled using information from Cubie HA. Diseases associated with human papillomavirus infection. 
Virology. 2013 Oct;445(1-2):21-34.
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level reached with Gardasil® is similar to the titers that are 
naturally induced by types 6 and 18 and greater for types 11 
and 16, whereas the plateau level with Cervarix® is much higher 
than that caused by the natural infection.16 
Contraindications and Side Effects
The vaccine is contraindicated in people with allergies to any of 
its components, and women should not be vaccinated during 
pregnancy even though it does not appear to increase the in-
cidence of miscarriage.26,27 Furthermore, people with immediate 
hypersensitivity towards yeast should not receive the Gardasil 
vaccine. The vaccine is not contraindicated for immunosuppres-
sed individuals or those with previous HPV infection, although 
immunogenicity is not guaranteed for the former class. Other 
vaccines may be administered before, during and after the cour-
se of HPV vaccination.26 Side effects which have been reported 
for the quadrivalent vaccine are: (1) pain, swelling and redness 
at the injection site and headache in more than 10% of recei-
vers; (2) bruising, itching, fever and nausea in more than 0.1%; 
(3) urticaria in less than 0.1%; and (4) bronchospasm in less 
than 0.01%.28
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sing consideration that vaccinating men against HPV is a wise 
decision as it serves a two-fold purpose. As HPV serotypes 16 
and 18 are implicated in 70% of anal cancers and precancerous 
lesions of the penis, the vaccine can reduce the incidence of 
these malignancies especially in homosexual males who are at 
increased risk of anal dysplasia. This is also relevant for the 
heterosexual population which practices anal intercourse, and 
it has been found that 35.9% of women and 42.3% of men be-
tween 18–44 years have anal intercourse with partners of the 
opposite sex.23 Furthermore, vaccinating men is also an indirect 
means of preventing HPV-induced cervical cancer in women, as 
it is a sexually transmitted disease.24 Unfortunately, people in 
low-income countries are less likely to be vaccinated against 
HPV due to its relatively high cost. In addition, most women in 
these countries do not have access to routine screening, with 
uptake of Pap smear estimated to be 5% within the past five 
years.25 This results in an overall higher mortality rate from cer-
vical cancer in developing countries. 
HPV Vaccines
There are currently two available vaccines against HPV: Gar-
dasil® by Merck Frost and Cervarix® by GlaxoSmithKline. Both 
vaccines contain virus-like particles (VLPs) that are synthesized 
using recombinant DNA technology and consist of the L1 protein 
component of the viral capsids.25 Such VLPs cause great respon-
se by the immune system and result in antibody titers which 
are much higher than those induced by the natural infection.16
Quadrivalent Vaccine
Gardasil® is said to be a quadrivalent vaccine because it targets 
four HPV serotypes, namely 6, 11, 16 and 18. The L1 capsid pro-
teins are synthesized in yeast cells (Saccharomyces cerevisae) 
and combined with an aluminum adjuvant. It is recommended 
for both sexes of ages 9–26 years and is administered in three 
doses at 0, 2 and 6 months. This vaccine can grant protection 
against ongoing HPV infection, precancer lesions of the cervix, 
vulva and vagina, as well as genital warts due to serotypes 
11, 16 and 18 in females of ages 16–26 years without previous 
infection.26
Bivalent Vaccine
On the other hand, Cervarix® is a bivalent vaccine which grants 
protection against two serotypes—HPV 16 and 18. The VLPs in 
this preparation are produced in insect cells using baculovirus 
with an adjuvant consisting of ASO4 and monophosphoryl lipid 
A from bacterial cell walls.16,26 The vaccine is indicated for girls/
women aged 10–25 years and is administered in three doses at 
0, 1 and 6 months. Randomized, controlled and double-blind 
studies with women aged 15–25 years demonstrated that the 
vaccine is efficient in preventing precursor lesions of cervical 
cancer due to HPV 16 and 18 in women having no previous 
infection.26
When observing the variation of antibody titer with time after 
the Gardasil® vaccine is administered, it is interesting to note 
that the variation in titer values after the Cervarix® vaccine fo-
llows the same profile, except for two differences. First, 24 mon-
ths after vaccination with Gardasil®, 96% of participants tested 
positive for HPV types 6, 11 and 16 antibodies and 68% for type 
18. Seropositivity reaches 100% for both HPV-16 and HPV-18 an-
tibodies at 51–53 months after vaccination. Second, the plateau 
Table 3. Cervical Cancer Biomarkers
Type of 
Biomarker
Test/Technique Remarks
HPV DNA 
testing
Hybrid Capture 2 (Qiagen) Detects 13 high-risk HPVs
Cervista HPV HR (Hologic) Detects 14 high-risk HPVs
Cervista HPV 16/18 
(Hologic)
Specifically identifies HPV 16 and 18
Cobas 4800 HPV (Roche 
Diagnostics)
Targets 14 high-risk HPVs
HPV RNA 
testing
APITMA (GenProbe) and 
OncoTect (IncellDX)
Based on reverse transcriptase and PCR technique and 
detect E6/E7 mRNA from 14 and 13 high-risk HPA sero-
types, respectively
PreTect HPV-Proofer (Nor-
chip) and NucliSENS EasyQ 
(Biomerieux)
Rely on nucleic acid sequence-based amplification (NAS-
BA) and are able to detect E6/E7 transcripts from HPV 16, 
18, 31, 33, 45
HPV protein 
testing
OncoE6 (Arbor Vita Cor-
poration)
Detects E6 protein encoded by HPV 16, 18, 45
Cytoactiv Assay (Cytoim-
mune Diagnostics)
Measures loss of expression of L1 which has been identi-
fied as a potential marker progressive lesions
Cellular 
biomarkers
P16/K1-67 Immunocyto-
chemistry Assay
p16 is a CDK-I whilst K1-67 is a proliferation antigen 
expressed in the G2 and M phases of the cell cycle. They 
are co-expressed in dysplastic lesions and constitute 
a highly sensitive and specific test for CIN2 or worse 
lesions
ProExCTM Assay (Bec-
ton-Dickinson)
Recognizes minichromosome maintenance protein 2 
and topoisomerase II α, which are expressed in cells 
with abnormal S-phases such as HPV-infected cells with 
increased E6/E7 synthesis.
Fluorescence In Situ 
Hybridization (FISH) and 
Multiplex Ligation-Depen-
dent Probe Amplification 
(MLPA)
Can be used to detect gain of chromosomes 3q and 5p 
which carry the TERC and TERT genes
Epigenetic 
biomarkers
Differential Methylation 
Hybridization (DMH)
Allows identification of SOX1, NKX6-1, PAX1, WX1 and 
LMXIA genes that are often methylated in cervical cancer 
and precancerous lesions
Restriction Landmark Ge-
nomic Scanning (RLGS)
Detection of methylated NOL4 and LHFPL4 genes
Demethylating agent + 
expression microarray
Identifies methylation of SPARC and TFP2 genes
Compiled using information from Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and 
cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 
2013;2013:519619.
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Conclusion
HPV infection plays an integral role in the development of cervi-
cal neoplasia. However, modern screening procedures coupled 
with the promotion of safe sexual practices and HPV vaccination 
can reduce the burden of this disease.
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